Opioid-Induced Bradycardia

Clinical Evidence and Risk Factors

The American Heart Association acknowledges that bradycardia is more likely to occur when hydromorphone is combined with other negative chronotropic agents such as beta-blockers, calcium channel blockers, or digoxin 1
The American College of Cardiology recognizes that patients with underlying cardiac disease are at a higher risk of bradycardia when administered hydromorphone 2
The American Heart Association notes that acidosis or hypoxia can increase the risk of bradycardia in patients receiving hydromorphone 2

The American College of Gastroenterology warns that combining hydromorphone with calcium channel blockers can have an additive effect on decreasing heart rate 3
The National Kidney Foundation advises that beta-blockers used concurrently with hydromorphone may potentiate bradycardia 1
The American Society of Anesthesiologists states that anesthetic agents used with opioids can further depress cardiac function 4

The American Society of Anesthesiologists recommends that atropine can be administered to reverse the bradycardia caused by opioid-induced parasympathetic stimulation 4

The American Heart Association suggests monitoring vital signs, particularly heart rate, when administering hydromorphone, especially in elderly patients or those with cardiac comorbidities 2
The American College of Gastroenterology advises monitoring vital signs when combining hydromorphone with other medications that can affect heart rate 3
The National Kidney Foundation recommends monitoring vital signs when administering hydromorphone, especially when combined with other negative chronotropic agents 1

The European Society of Cardiology notes that the risk of clinically significant bradycardia must be balanced against the need for adequate pain control 5
The American Society of Anesthesiologists warns that bradycardia may be more pronounced during the second phase of cardiac effects after opioid administration, which can last for several hours 4